Best Life Sciences Companies in Fremont, United States
The 62 best Life Sciences companies in Fremont, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Neuralink.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Fremont
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Neuralink 🦄 Provider of implantable brain-computer interfaces 78Funding top 15%Patents top 25%Moat top 25%Innovation top 27% All 10 signals ▾Fundingtop 15% Patentstop 25% Moattop 25% Innovationtop 27% Talenttop 28% Markettop 33% Growthtop 42% Techtop 44% Globalbottom 39% Newsbottom 24% Funding: Raised $680M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) Patents: 97 patents matched (strict assignee match) · 62 filings since 2022 vs 35 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $680M | 1 mo ago | 197 | Dongjin Seo Co-Founder | Series E | 97 patents High‑density, hermetic neural electrode arrays and wireless implant communication systems. | — |
| 2 | Think Surgical Developer of image-directed surgical robotic systems for orthopedic surgeries | $277M | 44 mo ago | 195 | — | Public | 439 patents Robotic orthopedic surgery navigation and bone registration for precise bone cutting. | — |
| 3 | Alamar Biosciences Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels 67News top 18%Funding top 19%Growth top 30%Moat top 31% All 9 signals ▾Newstop 18% Fundingtop 19% Growthtop 30% Moattop 31% Talenttop 35% Techtop 37% Markettop 44% Fin. healthbottom 46% Globalbottom 36% News: 15 BI events in 12 mo (of 30 tracked, 5 types) · +67% YoY Funding: Raised $250M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $250M | 5 mo ago | 83 | Steve Chen Co-Founder | Public | — | 1 internship · 1 launch · 1 expansion |
| 4 | Attovia Developer of antibody-based therapeutics for immune-mediated diseases and oncology 48Funding top 19%Talent top 28%Moat top 38%Global bottom 38% All 5 signals ▾Fundingtop 19% Talenttop 28% Moattop 38% Globalbottom 38% Marketbottom 37% Funding: Raised $165M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 48/100 | $165M | 14 mo ago | — | Zaneta Odrowaz Co-Founder | Series C | — | — |
| 5 | Zosano Pharma Developer of transdermal drug delivery systems for a broad range of therapeutic indications | $147M | 92 mo ago | 40 | — | Deadpooled | — | — |
| 6 | AngioScore Healthcare technology leader focused on improving health outcomes across the care continuum | $87M | 182 mo ago | 149 | Tom Trotter President & CEO | Acquired | 110 patents Patents concentrated in health & consumer products | — |
| 7 | Zeda Developer of medical devices to address the needs of the spine device market | $68M | 39 mo ago | 90 | Alexis Dang Co-Founder & CMO | Series B | — | — |
| 8 | Ardelyx Developer of therapeutics for the gastrointestinal tract, cardio-renal, GI, and metabolic diseases | $61M | 47 mo ago | 37 | Peter G Schultz Co-Founder | Public | 410 patents Oral phosphate transport inhibitors and formulations for kidney disease and hyperkalemia | 1 job opening · 1 internship |
| 9 | ARYx Therapeutics Retro Metabolic Drug design to retain efficacy | $55M | 190 mo ago | 56 | — | Public | — | — |
| 10 | Q’Apel Medical Provider of the medical device for the treatment of neurovascular interventions disorder | $52M | 49 mo ago | 87 | — | Series D | — | 1 launch |
| 11 | Velos Clinical research management solutions | $42M | 92 mo ago | 15 | — | Acquired | — | — |
| 12 | AlterG Provider of hardware and software solutions for rehabilitation | $39M | 56 mo ago | 44 | Charles Remsberg CEO | Acquired | 101 patents Anti‑gravity treadmill and differential air‑pressure systems for gait rehabilitation and training | — |
| 13 | Quark Pharmaceuticals Late stage pharmaceutical company developing RNAi-based therapeutics | $37M | 193 mo ago | 30 | Daniel Zurr Founder & CEO | Deadpooled | 475 patents Therapeutic nucleic acid agents for preventing ischemia‑reperfusion injury in organs | — |
| 14 | CV Ingenuity Drug coated balloon for treatment of Peripheral artery disease | $36M | 161 mo ago | — | Duke Rohlen ex-CEO | Acqui-Hired | 16 patents Drug‑eluting coating technologies for medical lumens and related device components | — |
| 15 | Averto Medical Developer of medical devices for patients suffering from gastrointestinal diseases | $33M | 21 mo ago | 18 | Kenton Fong Founder & CEO | Series A | — | — |
| 16 | Visunex Providing ophthalmic health information, eye care guidance, and vision-related solutions | $32M | 110 mo ago | 12 | Wei Su CEO | Series B | — | — |
| 17 | Vioptix Real-time tissue oxygen saturation measurement technology improving surgical outcomes | $32M | 184 mo ago | 12 12 → 15 (+25%) | Scott Coleridge CEO | Series E | 284 patents Non‑invasive tissue oxygen saturation monitoring devices and related sensor accessories. | — |
| 18 | RITA Medical Systems Products for oncology therapy | $31M | 250 mo ago | — | James Clemmer CEO & President | Acquired | — | — |
| 19 | Lyncean Tech Provider of imaging systems using local synchrotron X-ray source | $27M | 55 mo ago | 39 | — | Deadpooled | — | — |
| 20 | SpineView Surgical products for spine surgery | $25M | 186 mo ago | 25 | — | Deadpooled | — | — |
| 21 | ValGenesis Validation software for the life sciences companies | $24M | 11 mo ago | 431 431 → 677 (+57%) | — | Series B | 15 patents Software for risk‑based validation and lifecycle management of pharmaceutical manufacturing processes | — |
| 22 | DeVoro Medical Developer of medical devices for the treatment of cardiac diseases | $18M | 71 mo ago | 18 | — | Acquired | — | — |
| 23 | Celltrio Developer of automated biobanking and cell culture systems | $15M | 12 mo ago | 11 | — | Series B | 17 patents Cryogenic storage and handling systems for liquids and biological samples | 1 launch |
| 24 | Optovue Visionix: Innovating eye care with diagnostic, screening, refraction, and lab equipment | $10M | 230 mo ago | 90 | — | Acqui-Hired | 132 patents Patents concentrated in health & consumer products | — |
| 25 | Arbor Vita Innovating diagnostics and therapeutics for infectious diseases and cancers | $9M | 152 mo ago | 20 | Peter Lu Founder & CEO | Funding Raised | 183 patents Cellular protein extraction technologies and neurotherapeutics targeting PSD‑95 and stroke | — |
| 26 | Saset Healthcare Innovating medical ultrasound with advanced technologies for accurate diagnoses and remote support | $6M | — | 51 | Ravi Sethi Co-Founder & CEO | Early Stage | — | — |
| 27 | SeptRx Provider of minimally invasive device for treatment of heart defects | $3M | 180 mo ago | — | Scott Russell President | Series A | 13 patents Vascular embolic filtration systems and tissue expansion devices for therapeutic interventions | — |
| 28 | Probius Digital biochemical analysis tool for healthcare researchers | $2M | 10 mo ago | 14 | Roger Howe Co-Founder | Seed | — | — |
| 29 | Spartan Micro Neurovascular medical device company focused on innovative endovascular treatments | $2M | 78 mo ago | 4 | — | Seed | — | — |
| 30 | Handa Pharmaceuticals Specialty pharmaceutical company developing and commercializing high-quality prescription medications | $2M | 206 mo ago | 9 | Bill Liu President and CEO | Seed | — | — |
| 31 | WaferGen Biotechnology company providing innovative tools and services for life science research | $2M | 142 mo ago | 56 | — | Acquired | 56 patents Patents concentrated in transport & manufacturing processes | — |
| 32 | Dynatherm Medical Provider of solutions for treating and preventing hypothermia in surgical patients | $818K | 206 mo ago | — | — | Deadpooled | — | — |
| 33 | TheraJect Manufacturer of dissolving microneedle patches for drug delivery and vaccination | $680K | 166 mo ago | — | Sung-Yun Kwon Founder & CEO | Funding Raised | 46 patents Dissolvable microneedle arrays for transdermal vaccine and drug delivery | — |
| 34 | TrioWave Developer of a biostimulation device for pain management and aesthetics. | $400K | 146 mo ago | 1 | Huiyou Zhu Founder | Deadpooled | 5 patents Electrotherapy waveform generation, control, and personalized therapy device power management | — |
Top 12 Life Sciences companies in Fremont
#1
Series E · Fremont, California · founded 2016 · 197 employees$680Mraised▾
Provider of implantable brain-computer interfaces. It offers flagship product the N1 Implant the Link which is a coin-sized device designed to decode neural signals and enable users to control digital devices using only their thoughts. It also has an experimental device called Blindsight to restore vision in individuals with optic nerve damage by directly stimulating the visual cortex.
- May 2026Series E—
- May 2025Series E$650M
- Nov 2023Series D$43M
- Aug 2023Series D$323.2M
#2
Public · Fremont, California · founded 2018 · 83 employees$250Mraised▾
Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. The company's proprietary NULISA Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. Applications include clinical assay development, biomarker discovery and validation, and drug development.
- Jan 2026Series C$50M
- Feb 2024Series C$100M
- Sep 2021Series B$80M
- Jul 2020Grant (prize money)$321.9K
#3
Series C · Fremont, California · founded 2023$165Mraised▾
Developer of antibody-based therapeutics for immune-mediated diseases and oncology. The company leverages ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. It develops a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology.
- Apr 2025Series C$90M
- May 2024Series B$105M
- Feb 2024Series A$60M
#4
Series B · Fremont, California · founded 2005 · 431 employees$24Mraised▾
Validation software for the life sciences companies. It is the provider of integrated paperless validation lifecycle management software solutions for life sciences companies. Its flagship product ValGenesis Validation Lifecycle Management System has a regulatory framework and manages validation activities such as equipment, instruments, computer systems, cleaning, method, and process validation.
- Jul 2025Conventional Debt$16M
- May 2021Series B$24M
#5
Series B · Fremont, California · founded 2018 · 11 employees$15Mraised▾
Developer of automated biobanking and cell culture systems. It has developed CryoStor and RoboStor lines of liquid nitrogen freezers for biobanking applications. The company has also developed integrated robotic solutions which combine incubators, centrifuges and liquid handlers using software and LIMS systems.
- Jun 2025Series B$15M
#6
Series A · Fremont, California · founded 2016 · 18 employees$33Mraised▾
Developer of medical devices for patients suffering from gastrointestinal diseases. The company's products include ColoSeal intraluminal colonic diversion system, enables procedures such as colorectal cancer resection without the need to create an invasive temporary diverting stoma.
- Sep 2024Grant (prize money)$838.2K
- May 2024Series A$30M
- Nov 2023Seed$3M
- Aug 2021Grant (prize money)$353.5K
#7
Seed · Fremont, California · founded 2016 · 14 employees$2.4Mraised▾
Digital biochemical analysis tool for healthcare researchers. The company has developed software that assists with biological sample management and biochemical data analysis. It has features for sample analysis, data intelligence, cloud-based phenotypic data analysis, and more.
- Aug 2025Seed$2.4M
#8
Public · Fremont, California · founded 2007 · 195 employees$276.6Mraised▾
Developer of image-directed surgical robotic systems for orthopedic surgeries. It offers TSolution One the total knee application for fully automated bone preparation, TPLAN 3D Planning workstation is a computer system for preoperative planning and TCAT computer-assisted tool for preparing the bone cavity and joint surface.
- Oct 2022Post IPO$100M
- Sep 2022Post IPO$5.4M
- May 2022Post IPO$32M
- Apr 2022Post IPO$5M
#9
Series B · Fremont, California · founded 2017 · 90 employees$68.3Mraised▾
Developer of medical devices to address the needs of the spine device market. The company uses 3D printing and nanotechnologies to create medical devices for spine injuries. Also, it offers products for other industries such as aerospace, defense, space, and energy.
- Mar 2023Series B$52M
- Mar 2023Conventional Debt—
- Dec 2020Series A$16.3M
#10
Public · Fremont, California · founded 2007 · 37 employees$61.1Mraised▾
Developer of therapeutics for the gastrointestinal tract, cardio-renal, GI, and metabolic diseases. Its lead product, Tenapanor (RDX5791), a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and hyperphosphatemia in chronic kidney disease patients on dialysis. Also developing RDX002, treatment of high potassium, or hyperkalemia, in kidney and heart disease patients.
- Jun 2022Post IPO—
- Nov 2019Post IPO$20M
- May 2018Conventional Debt$50M
- Jul 2016Post IPO$110M
#11
Deadpooled · Fremont, California · founded 2006 · 40 employees$147.2Mraised▾
Developer of transdermal drug delivery systems for a broad range of therapeutic indications. The company's lead product candidates include daily ZP-PTH for severe osteoporosis, ZP-Glucagon, for severe hypoglycemia, and ZP-Triptan for migraine. The company has developed a proprietary transdermal microneedle patch system to administer molecules through the skin for the treatment of a variety of indications.
- Sep 2018Venture Debt$14M
- 2018Post IPO—
- Aug 2016Post IPO$7.5M
- Jan 2015Post IPO$15M
#12
Series D · Fremont, California · founded 2019 · 87 employees$51.9Mraised▾
Provider of the medical device for the treatment of neurovascular interventions disorder. The company offers the flagship products Walrus balloon-based catheter system and Wahoo which is a hybrid-access and dual-mode catheter system. The device helps the clinician in the insertion and guidance of an intravascular catheter, trackable catheter platform, flow control, traceability support for the treatment of neurovascular disorders like clots, stroke among others.
- May 2022Series D$29.9M
- Feb 2021Series C$22M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.